Abcam, ab310987-100µL, Alexa Fluor® 488 Anti-Iba1 antibody [EPR16589] - Microglia marker

Product details
What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on recombinant antibodies.
Patented technology Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
Iba1 modulates actin bundling facilitating changes in microglial morphology and motility. It does not form part of a multiprotein complex but is significantly involved in cytoskeletal dynamics. This protein's expression increases during brain injury indicating its role in response to neural trauma. Iba1 has calcium-binding properties which suggest that it might interact with proteins involved in calcium signaling pathways.
Pathways
Calcium signaling and actin cytoskeletal rearrangement are significant biological processes that involve Iba1. Within these pathways Iba1 interacts closely with other actin-binding proteins that affect microglial movement and morphology. Such interactions illustrate how Iba1 helps microglia navigate and respond to changes within the brain environment.